Progress of cytokine release syndrome in children CAR-T cell therapy / 国际儿科学杂志
International Journal of Pediatrics
;
(6): 793-798, 2022.
Artículo
en Chino
| WPRIM
| ID: wpr-989014
ABSTRACT
As a disruptive therapeutic technique, chimeric antigen receptor T-cell (CAR-T)immunotherapy has achieved a revolutionary breakthrough in pediatric patients with relapsed/refractory acute lymphoblastic leukemia(ALL). Using genetic engineering technology, T lymphocytes can be modified to express CAR on the surface, which then target tumor-specific antigens and exert cytotoxic effects against tumor cells.However, CAR-T therapy may cause some serious adverse reactions, of which the most common and noticeable is cytokine release syndrome(CRS). Inappropriate medical management of CRS will lead to severe complications and can be even life-threating.In this review, we mainly discuss the progress of CRS in the CAR-T therapy of children ALL from the aspects of the mechanism, clinical manifestations, grading systems and clinical treatment.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Idioma:
Chino
Revista:
International Journal of Pediatrics
Año:
2022
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS